ADMA Biologics (ADMA) has issued an announcement.
ADMA Biologics, Inc. has made key decisions regarding executive compensation, including approving a substantial base salary and performance-related cash bonuses for CEO Adam Grossman, reflecting overachievement of 2023’s corporate goals. Additionally, the Board, on the advice of the Compensation Committee, has set equity grants for non-employee directors and ownership guidelines to strengthen vested interests in the company. In a notable transition, CFO Brian Lenz will move to a consultancy role, with a search for his full-time successor underway and CEO Grossman taking on interim CFO duties.
Learn more about ADMA stock on TipRanks’ Stock Analysis page.
